1. Home page
  2. Search

Hyperthermic intraperitoneal chemotherapy for management of gastrointestinal and biliary tract malignancies: a systematic review and meta-analysis of randomized trials

This item is provided by the institution :
Hellenic Society of Gastroenterology   

Repository :
Annals of Gastroenterology   

see the original item page
in the repository's web site and access all digital files if the item*



Hyperthermic intraperitoneal chemotherapy for management of gastrointestinal and biliary tract malignancies: a systematic review and meta-analysis of randomized trials (EN)
Gogadis, Aristeidis
Filis, Panagiotis
Kamposioras, Konstantinos
Kanellopoulou, Afroditi
Mauri, Davide
Filis, Nikolaos
Kapoulitsa, Fani
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
2022-12-25
Background Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) promised to transform the management of peritoneal carcinomatosis (PC). Forty years since the introduction of the technique, published data from randomized controlled trials (RCTs) remain scarce. We assessed the cumulative comprehensive available evidence on the use of HIPEC in gastrointestinal (GI) and biliary tract malignancies and established the current benchmark for GI HIPEC research in both the prevention and treatment of peritoneal metastases. Methods RCTs were identified through a systematic search of Medline, Cochrane and Embase databases. Overall survival and progression-free survival were the outcomes of interest. Results The search resulted in 13 RCTs for gastric cancer (10 on prophylactic and 3 on therapeutic HIPEC), 4 for colorectal cancer (2 on prophylactic and 2 on therapeutic HIPEC), and 1 for pancreatic cancer. No RCTs were identified that included other types of GI or biliary tract cancers. Current randomized evidence does not support any overall survival benefit from the use of HIPEC in the adjuvant setting for gastric cancer or for colorectal cancer in any setting. Despite the survival benefit noticed in the treatment of PC from gastric cancer (risk ratio 0.85, 95% confidence interval 0.77-0.93; P<0.001), the results were derived from only 190 patients. Conclusions The current evidence from RCTs does not support the use of HIPEC in the treatment/ prevention of PC in GI and biliary tract malignancies. HIPEC should continue to be considered experimental until level 1 evidence from properly designed international multicenter studies becomes available. Keywords Hyperthermic intraperitoneal chemotherapy, gastrointestinal cancer, gastric cancer, biliary tract cancer, colorectal cancer Ann Gastroenterol 2023; 36 (1): 87-96 (EN)
English
Hellenic Society of Gastroenterology (EN)
1792-7463
1108-7471
Annals of Gastroenterology; Volume 36, No 1 (2023); 87 (EN)
Copyright (c) 2022 Annals of Gastroenterology (EN)
Hellenic Society of Gastroenterology
Annals of Gastroenterology
Original Articles



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)